Article Text

Download PDFPDF
Porphyria for the neurologist: the bare essentials
  1. T J Peters1,
  2. K R Mills2
  1. 1Head of Department of Clinical Biochemistry, King’s College Hospital, London, UK
  2. 2Professor of Clinical Neurophysiology Department of Clinical Neurophysiology, King’s College Hospital, London, UK
  1. Correspondence to:
 Professor K R Mills, Department of Clinical Neurophysiology, King’s College Hospital, Denmark Hill, Camberwell, London SE5 9RS, UK;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The porphyrias are a heterogeneous group of disorders in which one or more of seven enzymes of haem biosynthesis show reduced activities due to inherited genetic abnormalities (table and fig) or secondary enzyme inhibition. Of particular concern to the neurologist are the four genetic neuropsychiatric porphyrias, in order of decreasing prevalence: acute intermittent porphyria, variegate porphyria, hereditary coproporphyria, and the extremely rare Doss porphyria. The overall prevalence of symptomatic acute porphyria is about 1 in 50,000. Relevant causes of secondary porphyria include chronic lead poisoning, hereditary tyrosinaemia, hexachlorbenzene poisoning, and liver disease including alcoholism and iron overload.

View this table:

The genetic porphyrias


The pathway for the biosynthesis of heme. Ac, acetic -CH2COO-; ALAD, ALA dehydratase; ALAS, ALA synthase; COX, coproporphyrignogen oxidase; FECH, ferrochelatase; HMBS, HMB synthase; PPOX, protoporphyrinogen oxidase; Pr, propionic –CH2CH2COO–; UROD, uroporphyrinogen decarboxylase; UROS, uroporphyrinogen III synthase; Vi, vinyle –CH:CH2. (Reprinted from Biochemistry Illustrated, 5th Edition. Campbell et al, © 2005 with permission from Elsevier.)

The hallmark of active or symptomatic porphyria is increased excretion of porphobilinogen (PBG) and amino-laevulinic acid (ALA). As only 10% of individuals who inherit the genetic defect develop the overt clinical features with raised excretion profiles, a normal excretion of these metabolites does not exclude inheritance of the defect but does exclude porphyria as a cause of the present symptoms. In between attacks the excretion of ALA and PBG may be normal …

View Full Text